Deoxycytidine kinase modulates the impact of the ABC transporter ABCG2 on clofarabine cytotoxicity

Cancer Research

Volumn 71, Issue 5, 2011, Pages 1781-1791

  Nagai, Shinjiro ^a   Takenaka, Kazumasa ^a   Nachagari, Deepa ^a   Rose, Charles ^a   Domoney, Kali ^a   Sun, Daxi ^a   Sparreboom, Alex ^a   Schuetz, John D ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CLOFARABINE; DEOXYCYTIDINE KINASE; DRUG METABOLITE; MITOXANTRONE; SMALL INTERFERING RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL PROLIFERATION; COMPARATIVE GENOMIC HYBRIDIZATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG METABOLISM; DRUG UPTAKE; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENETIC VARIABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM;

ADENINE NUCLEOTIDES; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; DEOXYCYTIDINE KINASE; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOBLOTTING; MUTAGENESIS, SITE-DIRECTED; NEOPLASM PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 79952210590     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1919     Document Type: Article

References (27)

1. Borst P, Balzarini J, Ono N, Reid G, de Vries H, Wielinga P, et al. The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy. Antiviral Res 2004;62:1-7. (Pubitemid 38340742)
2. Rose JB, Coe IR. Physiology of nucleoside transporters: back to the future. Physiology (Bethesda) 2008;23:41-8.
3. Carson DA, Wasson DB, Esparza LM, Carrera CJ, Kipps TJ, Cottam HB. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino- fluoro-2'-deoxyadenosine. Proc Natl Acad Sci U S A 1992;89:2970-4.
4. Parker WB, Shaddix SC, Chang CH, White EL, Rose LM, Brockman RW, et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res 1991;51:2386-94.
5. Robertson LE, Chubb S, Meyn RE, Story M, Ford R, Hittelman WN, et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-20-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine. Blood 1993;81:143-50. (Pubitemid 23013688)
6. Gandhi V, Plunkett W, Bonate PL, Du M, Nowak B, Lerner S, et al. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment. Clin Cancer Res 2006;12:4011-7. (Pubitemid 44078088)
7. Jeha S, Gandhi V, Chan KW, McDonald L, Ramirez I, Madden R, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004;103:784-9. (Pubitemid 38129533)
8. Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003; 102:2379-86. (Pubitemid 37193573)
9. Lindemalm S, Liliemark J, Gruber A, Eriksson S, Karlsson MO, Wang Y, et al. Comparison of cytotoxicity of 2-chloro- 2′-arabino-fluoro-2′- deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia. Haematologica 2003;88:324-32. (Pubitemid 36358721)
10. Parker WB, Secrist JA 3rd, Waud WR. Purine nucleoside antimetabolites in development for the treatment of cancer. Curr Opin Investig Drugs 2004;5:592-6.
11. Bonate PL, Arthaud L, Cantrell WR Jr., Stephenson K, Secrist JA 3rd, Weitman S. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 2006;5:855-63. (Pubitemid 44480539)
12. Gandhi V, Plunkett W. Clofarabine and nelarabine: two new purine nucleoside analogs. Curr Opin Oncol 2006;18:584-90. (Pubitemid 44427632)
13. Lotfi K, Mansson E, Spasokoukotskaja T, Pettersson B, Liliemark J, Peterson C, et al. Biochemical pharmacology and resistance to 2-chloro-20-arabino-fluoro-20-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin Cancer Res 1999;5:2438-44. (Pubitemid 29437325)
14. Damaraju VL, Damaraju S, Young JD, Baldwin SA, Mackey J, Sawyer MB, et al. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 2003; 22:7524-36. (Pubitemid 37487174)
15. Mansson E, Spasokoukotskaja T, Sallstrom J, Eriksson S, Albertioni F. Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line. Cancer Res 1999;59:5956-63. (Pubitemid 30004957)
16. Lamba JK, Crews K, Pounds S, Schuetz EG, Gresham J, Gandhi V, et al. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther 2007;323:935-45. (Pubitemid 350146062)
17. Adachi M, Sampath J, Lan LB, Sun D, Hargrove P, Flatley R, et al. Expression of MRP4 confers resistance to ganciclovir and compromises bystander cell killing. J Biol Chem 2002;277:38998-9004. (Pubitemid 35154766)
18. de Wolf C, Jansen R, Yamaguchi H, de Haas M, van de Wetering K, Wijnholds J, et al. Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther 2008;7:3092-102.
19. Wielinga PR, Reid G, Challa EE, Van Der Heijden I, van Deemter L, de Haas M, et al. Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol Pharmacol 2002;62: 1321-31. (Pubitemid 35407456)
20. Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F, et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A 2000;97:7476-81. (Pubitemid 30431488)
21. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, et al. MRP4: a previously unidentified factor in resistance to nucleoside- based antiviral drugs. Nat Med 1999;5:1048-51. (Pubitemid 29439577)
22. Sarkadi B, Homolya L, Szakacs G, Varadi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 2006;86:1179-236. (Pubitemid 44521651)
23. Takenaka K, Morgan JA, Scheffer GL, Adachi M, Stewart CF, Sun D, et al. Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Res 2007;67:6965-72. (Pubitemid 47105544)
24. King KM, Damaraju VL, Vickers MF, Yao SY, Lang T, Tackaberry TE, et al. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol Pharmacol 2006;69:346-53. (Pubitemid 43048921)
25. Sabini E, Ort S, Monnerjahn C, Konrad M, Lavie A. Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. Nat Struct Biol 2003;10:513-9. (Pubitemid 36792901)
26. Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S. Clofarabine: past, present, and future. Leuk Lymphoma 2007;48:1922-30. (Pubitemid 47542978)
27. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009;15:6062-9.